Investor Presentaiton

LAG-3 Cluster: IBI-110 (LAG-3 mAb) and IBI-323 (PD-L1/LAG-3 Bispecific Antibody) Development Plan Overview IBI-110 Clinical Highlights Phase 1 study data released on 2021 ASCO: Promising preliminary results with good safety profile and anti-tumor activities • - Well tolerated. No DLT observed - Good safety profile. TRAE mostly grade 1-2 Anti-tumor activity observed in both monotherapy and combo therapy in Phase 1 IBI-110 Development Program Overview • IBI-323 Preclinical Highlights Dual blockade of LAG-3 and PD-L1. Blocking LAG-3 can also inhibit the negative regulatory effect of Treg's, with a stronger and longer-lasting T- cell activity potential than single target. With bridging effect as bispecific antibody, tumor cells expressing PD-L1 can be closer to T cells expressing LAG-3, thus forming a stable TCR:MHC immune synapse that further activates T cells. IBI-323 Development Program Overview Phase 1 study completed Phase 1 study started Clinical Clinical Completed patient for Phase 1a and Phase 1b study of IBI-100 in 2021.01 progress progress Dosed the first patient of Phase 1 study for IBI-323 for advanced malignant tumors Publish the Phase 1 study data of IBI-110 at 2021 ASCO Phase 1b and Phase 2 studies to start Phase 1 study ongoing 2021 plan 2021 plan Will start multiple Phase1b and Phase2 studies to explore the potential of IBI110 in different tumor types To keep enrolling patients for the Phase 1 study of IBI-323 Leading and highly differentiated position in LAG-3 with IBI-110 (LAG-3 mAb) moving fast to get PoC in 2021, and IBI-323 (PD-L1/LAG-3) in Phase 1 with novel biological mechanism and potential strong synergy. Innovent Confidential Copyright©2021 Innovent Biologics 30

View entire presentation